FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2138145418> ?p ?o ?g. }

• W2138145418 endingPage "157" @default.
• W2138145418 startingPage "149" @default.
• W2138145418 abstract "Onychomycosis is common, accounting for up to 50% of all nail disorders. Toenail onychomycosis can cause nail deformity, embarrassment, pain and walking difficulties. Some populations, such as individuals with diabetes, are at higher risk for developing secondary complications such as infections. Treatment takes many months and therapeutic choices can increase clinical effectiveness, lower toxicity and minimize healthcare costs.Based on the results of a previous pilot study, the objective of the present study was to show, in a larger population, the enhanced efficacy of a combination of amorolfine nail lacquer and oral terbinafine in the treatment of onychomycosis with matrix involvement. In addition, a cost-effectiveness analysis was performed.In this multicentre, randomized, open-label, parallel group study, patients were randomized to receive either a combination of amorolfine hydrochloride 5% nail lacquer once weekly for 12 months plus terbinafine 250 mg once daily for 3 months (AT group) or terbinafine alone once daily for 3 months (T group). The study duration was 18 months including a 6-month treatment-free phase following the 12-month active treatment phase for the AT group and a 15-month treatment-free phase following the 3-month active treatment phase for the T group. The primary efficacy criterion was overall response, dichotomized into success or failure, success being the combination of clinical cure and negative mycology at month 18. This criterion was used as the effectiveness measure in the pharmacoeconomic analysis, conducted from a payer perspective.In total, 249 patients were included into the study: 120 in the AT group and 129 in the T group. A significantly higher success rate was observed for patients in the AT group relative to those in the T group at 18 months (59.2% vs. 45.0%; P = 0.03). Both treatment regimens were safe and well tolerated. Treatment cost per cured patient was lower for the combination than for terbinafine alone in all countries.Study results confirmed that, in the treatment of dermatophytic toenail onychomycosis with matrix involvement, amorolfine nail lacquer in combination with oral terbinafine enhances clinical efficacy and is more cost-effective than terbinafine alone." @default.
• W2138145418 created "2016-06-24" @default.
• W2138145418 creator A5003507854 @default.
• W2138145418 creator A5027619579 @default.
• W2138145418 creator A5028006147 @default.
• W2138145418 creator A5041025684 @default.
• W2138145418 creator A5045634965 @default.
• W2138145418 creator A5062068107 @default.
• W2138145418 creator A5072876470 @default.
• W2138145418 creator A5087003645 @default.
• W2138145418 date "2007-07-01" @default.
• W2138145418 modified "2023-10-16" @default.
• W2138145418 title "A multicentre, randomized, controlled study of the efficacy, safety and cost-effectiveness of a combination therapy with amorolfine nail lacquer and oral terbinafine compared with oral terbinafine alone for the treatment of onychomycosis with matrix involvement" @default.
• W2138145418 cites W1551821781 @default.
• W2138145418 cites W1971220684 @default.
• W2138145418 cites W1977168223 @default.
• W2138145418 cites W1982740731 @default.
• W2138145418 cites W1992263972 @default.
• W2138145418 cites W2003283881 @default.
• W2138145418 cites W2023767868 @default.
• W2138145418 cites W2024951429 @default.
• W2138145418 cites W2058813334 @default.
• W2138145418 cites W2070140704 @default.
• W2138145418 cites W2085549481 @default.
• W2138145418 cites W2090295892 @default.
• W2138145418 cites W2095051720 @default.
• W2138145418 cites W2106242890 @default.
• W2138145418 cites W2115445021 @default.
• W2138145418 cites W2131368811 @default.
• W2138145418 cites W2158689487 @default.
• W2138145418 cites W2163914269 @default.
• W2138145418 cites W2413817970 @default.
• W2138145418 cites W4234797107 @default.
• W2138145418 cites W4254242850 @default.
• W2138145418 cites W4254398305 @default.
• W2138145418 doi "https://doi.org/10.1111/j.1365-2133.2007.07974.x" @default.
• W2138145418 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17553051" @default.
• W2138145418 hasPublicationYear "2007" @default.
• W2138145418 type Work @default.
• W2138145418 sameAs 2138145418 @default.
• W2138145418 citedByCount "90" @default.
• W2138145418 countsByYear W21381454182012 @default.
• W2138145418 countsByYear W21381454182013 @default.
• W2138145418 countsByYear W21381454182014 @default.
• W2138145418 countsByYear W21381454182015 @default.
• W2138145418 countsByYear W21381454182016 @default.
• W2138145418 countsByYear W21381454182017 @default.
• W2138145418 countsByYear W21381454182018 @default.
• W2138145418 countsByYear W21381454182019 @default.
• W2138145418 countsByYear W21381454182020 @default.
• W2138145418 countsByYear W21381454182021 @default.
• W2138145418 countsByYear W21381454182022 @default.
• W2138145418 countsByYear W21381454182023 @default.
• W2138145418 crossrefType "journal-article" @default.
• W2138145418 hasAuthorship W2138145418A5003507854 @default.
• W2138145418 hasAuthorship W2138145418A5027619579 @default.
• W2138145418 hasAuthorship W2138145418A5028006147 @default.
• W2138145418 hasAuthorship W2138145418A5041025684 @default.
• W2138145418 hasAuthorship W2138145418A5045634965 @default.
• W2138145418 hasAuthorship W2138145418A5062068107 @default.
• W2138145418 hasAuthorship W2138145418A5072876470 @default.
• W2138145418 hasAuthorship W2138145418A5087003645 @default.
• W2138145418 hasConcept C126322002 @default.
• W2138145418 hasConcept C141071460 @default.
• W2138145418 hasConcept C16005928 @default.
• W2138145418 hasConcept C168563851 @default.
• W2138145418 hasConcept C191897082 @default.
• W2138145418 hasConcept C192562407 @default.
• W2138145418 hasConcept C2776999253 @default.
• W2138145418 hasConcept C2777071850 @default.
• W2138145418 hasConcept C2777852167 @default.
• W2138145418 hasConcept C2778236110 @default.
• W2138145418 hasConcept C2779548794 @default.
• W2138145418 hasConcept C2908647359 @default.
• W2138145418 hasConcept C71924100 @default.
• W2138145418 hasConcept C99454951 @default.
• W2138145418 hasConceptScore W2138145418C126322002 @default.
• W2138145418 hasConceptScore W2138145418C141071460 @default.
• W2138145418 hasConceptScore W2138145418C16005928 @default.
• W2138145418 hasConceptScore W2138145418C168563851 @default.
• W2138145418 hasConceptScore W2138145418C191897082 @default.
• W2138145418 hasConceptScore W2138145418C192562407 @default.
• W2138145418 hasConceptScore W2138145418C2776999253 @default.
• W2138145418 hasConceptScore W2138145418C2777071850 @default.
• W2138145418 hasConceptScore W2138145418C2777852167 @default.
• W2138145418 hasConceptScore W2138145418C2778236110 @default.
• W2138145418 hasConceptScore W2138145418C2779548794 @default.
• W2138145418 hasConceptScore W2138145418C2908647359 @default.
• W2138145418 hasConceptScore W2138145418C71924100 @default.
• W2138145418 hasConceptScore W2138145418C99454951 @default.
• W2138145418 hasIssue "1" @default.
• W2138145418 hasLocation W21381454181 @default.
• W2138145418 hasLocation W21381454182 @default.
• W2138145418 hasOpenAccess W2138145418 @default.
• W2138145418 hasPrimaryLocation W21381454181 @default.
• W2138145418 hasRelatedWork W119079129 @default.
• W2138145418 hasRelatedWork W134615286 @default.
• W2138145418 hasRelatedWork W1983953981 @default.

• next